Monthly Archives - March 2007

Free HIV lecture in Houston on April 19, 2007

Title: Latest Update on HIV Research

Seminar date : April 19, Thursday

Time: 6:00 pm til 8:30 pm

Free dinner and door prizes

Speakers: Shannon Schrader MD
Nelson Vergel (

United Way of the Texas Gulf Coast
50 Waugh Drive
Houston, Texas 77007

For more information email :

Letter to the FDA about ways to improve Expanded Access Programs of Investigational Drugs in HIV

From a meeting held by the Forum of Collaborative HIV Research. The list of participants is at the end of the letter. I certainly hope that the FDA encourages industry to implement these recommendations. Great ideas have died due to lack of action.

March 11, 2007

The Forum for Collaborative HIV Research, an independent public/private partnership that includes government agencies, pharmaceutical and diagnostic industries, HIV researchers and clinicians, payers, foundations, and the HIV patient advocacy community organized a roundtable discussion on February 16, 2007 to discuss how current and future HIV antiretroviral expanded access programs (EAPs) might be improved so that they best meet the needs of patients, clinicians, industry sponsors, and regulatory agencies. This roundtable meeting was the first opportunity for all of the relevant parties to talk about improving expanded access programs for antiretroviral agents. As such, it was a valuable opportunity not only to listen to the concerns and perspectives of the various constituencies, but also to realize how much their interests align in support of providing access to therapies for patients with few treatment options.

We submit the following comments and recommendations to the FDA Docket No. 2006N-0062 and RIN 0910-AF14.

Introductory comments:

Expanded access programs were developed in order to make promising treatments available to patients who need them as early in the drug evaluation process as possible. In particular, the goal is to make such drugs available to patients who have exhausted all currently approved therapies. Early in the HIV epidemic, HIV activist organizations challenged the existing drug approval system as too cautious, particularly in the face of a deadly epidemic that was claiming thousands of lives for lack of effective therapies. Their efforts shifted the balance from the strictly protective model with an emphasis on preventing harm to patients toward increasing access to potentially effective therapies for patients who are in need.

The HIV field likely has the most experience with expanded access programs compared to other diseases. Twenty-one drugs have previously been made available through expanded access programs in the United States and an additional three drugs are currently available through expanded access programs for people living with HIV.

At present, the approach to EAPs is to have each company’s program (independent of other companies) precede the release of new antiretrovirals prior to FDA approval. Major concerns to this approach within the HIV scientific, medical and activist communities include the increased risk of drug resistance when adding a single new agent to a failing regimen (or “virtual monotherapy”), potentially leading to a transient response but reduced long-term durability; and the risks associated with using untested combinations of drugs before the potential for drug interactions has been systematically studied.

Key issues in HIV-therapy related EAPs:

The size of the patient population that currently needs access to investigational antiretroviral drugs is difficult to estimate. We recognize that such patients do still exist and that the size of the population is probably decreasing, but convincing data to indicate the number of patients in need of early access is lacking. In addition to the criteria of failing a third regimen, a key factor in the equation is the urgency of the patient’s need for new therapy.
Tension exists between the clinical and research aspects of EAPs. While the primary rationale for EAPs is to provide early access to drugs for patients in need, there are secondary competing interests in terms of the requirements to collect useful safety data on emerging compounds that might identify unknown safety issues and ultimately help guide treatment strategies. However, current data collection practices rarely yield useful information.
EAPs are associated with a heavy administrative burden that limits the ability of some sites to participate and these programs are unfunded or underfunded. This burden appears to be particularly acute in the academic research setting, where intensive IRB approval and oversight combined with the data collection requirements of the protocols has forced some centers to forego participation in EAPs until they can find a way to pay for them. As sites refuse to participate, this limits patient access to the EAP.
EAPs need to be conceived of within the context of clinical strategies overall. As the HIV epidemic and antiretroviral treatment strategies have evolved, it is no longer advisable to give patients new drugs without ensuring other active agents in the regimen. Otherwise patients would effectively be receiving virtual monotherapy and risk the development of drug resistance and subsequent regimen failure.
Geographic limitations continue to impede access for patients in small cities and in rural areas. Ideally, the system should be able to provide access to experimental drugs for all patients who need them and qualify for EAPs regardless of where they live.
Information about the EAPs can be quite difficult to find. Some companies do not list sites participating in their EAP on their own websites or on database websites like, making it very difficult for patients and their physicians to know where they might access experimental agents outside of clinical trials. Similarly, companies may not adequately advertise the existence of their EAPs. Industry is particularly concerned about the perceived appearance of pre-approval marketing.

Specific Recommendations:

· Explore the potential for standardization of EAP data collection requirements and safety reporting. This could reduce the redundancy in the current system and simplify participation in multiple simultaneous EAPs.

· Consider further collaboration between regulatory agencies and the pharmaceutical companies in the design of EAPs to include the simultaneous use of multiple investigational agents and to identify creative study designs that will limit the use of virtual monotherapy and address the evolving therapeutic needs of patients.

· Explore standardizing EAP protocols so that some of the administrative work (example being submission to IRBs) can be lessened.

· Explore the potential collaboration between the FDA and other regulatory bodies to standardize and minimize the burden, as much as possible, for the very complex and variable regulatory requirements for EAPs.

· Explore how the pharmaceutical companies can standardize their EAPs in terms of development of case report forms and adverse events reporting.

· Provide guidance to contract research organizations (CROs) on data collection requirements such that the administrative burden for an EAP is reduced compared to a standard clinical trial.

· Apply and take advantage of technological modernization in adverse event reporting. For example, a centralized electronic database could provide access to basic tabulation and analysis of the voluminous serious adverse event reports that in their present form are virtually useless to the individual site investigators and site IRBs.

· Consider a two tiered expanded access approach: one would be an actual research protocol designed to address specific questions leading to approval, and which would be appropriately reimbursed like any other clinical trial. Such a protocol could address the types of issues normally studied in Phase 4 studies. These could be designed to target underrepresented patient populations. The second parallel approach could be a simplified protocol, similar to the current EAP protocols. However, both tiers likely would need reimbursement to participating institutions due to non-recovered costs of participation in the EAP.

A full report from this roundtable discussion will be available on the Forum for Collaborative HIV Research’s website at

Forum for Collaborative HIV Research

Rethinking the Approach to Expanded Access Programs

February 16, 2007

Washington, D.C.

Valerianna Amorosa, M.D.

University of Pennsylvania

Christine Balt, M.S., R.N., APRN-BC, AACRN
Indiana University Division of Infectious Diseases

Association of Nurses in AIDS Care

Debra Birnkrant, M.D.


Rob Camp


Ben Cheng, M.Sc.

Forum for Collaborative HIV Research

Joel Gallant, M.D., M.P.H.

Johns Hopkins University School of Medicine

Roy Gulick, M.D., M.P.H.

Cornell University

Michael Horberg, M.D., M.A.S., F.A.C.P.

Kaiser Permanente

Ernest Igwacho

Forum for Collaborative HIV Research

Daniel Kuritzkes, M.D.

Harvard Medical School

Katherine Laessig, M.D.


Randi Leavitt, M.D., Ph.D.

Merck & Co., Inc.

Meagan Lyon, M.P.H

Forum for Collaborative HIV Research

Bill Mannion, R.N., B.S.N.

Pfizer, Inc.

Karen Manson

Tibotec BVBA

Kendall Marcus, M.D.


Scott McCallister, M.D.

Panacos Pharmaceuticals

Marita McDonough, R.N., M.P.A.

Boehringer Ingelheim Pharmaceuticals, Inc.

Luis Mendao

European Aids Treatment Group

Veronica Miller, Ph.D.

Forum for Collaborative HIV Research

Nathalie Morgensztejn

EMEA representative for the HIV Forum

Jeff Murray, M.D., M.P.H.


Linda Onaga
Forum for Collaborative HIV Research

Frederick Schmid, D.V.M., M.B.A.
Panacos Pharmaceuticals

Kimberly Struble, Pharm.D.
Pablo Tebas, M.D.
University of Pennsylvania

Randall Tressler, M.D.
Pfizer, Inc.

Nelson Vergel, B.Ch.E., M.B.A

Douglas Ward, M.D.

Dupont Circle Physicians Group

Eric Zechman

Medical Writer

Do not do as I did

Please read the article written by Enid Vazquez in the latest Positively Aware, one of the main free HIV magazines distributed around the U.S.

My comments are in the last part in the section called “Don’t do as I did”

I want to make sure that people who are applying for TMC 125 expanded access are very careful when assuming that this medication will be represent an “active” agent. No genotype test for EAP drugs is available, so we are in danger of assuming that a new drug is an active drug (this assumption may not be true when starting drugs in existing classes). An active drug is one that is shown in your resistance test (genotype or phenotype) to have a good chance to work in controlling your virus. Another danger with TMC 125 is that it is a NNRTI and we know that prior NNRTI resistance can be archived and not show up in genotype tests. Many patients like myself with extensive NNRTI resistance in the past show activity to that class in our genotype test. If the doctor does not carefully review prior medication history and asks the right questions to the patient, both the doctor and patient will assume that there is no archived prior resistance. So be very careful!

If you are to start a new combo with MK 518 integrase inhibitor, a drug that is showing more promise than most for patients with multidrug resistance, make sure that you start it with Fuzeon (if you are Fuzeon naive) and/or Maraviroc (if you have a R5 tropic virus) unless you can be 100 % certain that TMC 125 will work on your virus. With all the hype surrounding TMC 114, I made the terrible assumption about the activity of TMC 114 (Darunavir, Prezista) when I got that drug via EAP to start it with MK 518 as part of Merck’s phase III study. Read more in the link below.

Around 30 % of people who have extensive Kaletra and protease resistance may have pre-existing resistance to Aptivus (Tipranavir) and/or Prezista (Darunavir). No one is talking about this and there are a few conference posters on the subject but not discussed by anyone. Do not fall prey of the hype that is built around new medications, unless they are in a new class that you have never taken before and that show great response. This is the best chance for many of us to attain undetectable virus and hopefully keep it that way for a long time, if you do it right the first time.